Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 9 for:    sm04690

A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02536833
Recruitment Status : Completed
First Posted : September 1, 2015
Last Update Posted : March 13, 2020
Sponsor:
Information provided by (Responsible Party):
Samumed LLC

Brief Summary:
The purpose of this study is to assess the efficacy, safety, and tolerability of three different strengths of SM04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis subjects.

Condition or disease Intervention/treatment Phase
Osteoarthritis Drug: SM04690 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 455 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
Actual Study Start Date : September 9, 2015
Actual Primary Completion Date : April 20, 2017
Actual Study Completion Date : April 20, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: SM04690, 0.03mg/2mL
Single intra-articular injection of SM04690
Drug: SM04690
Experimental: SM04690, 0.07mg/2mL
Single intra-articular injection of SM04690
Drug: SM04690
Experimental: SM04690, 0.23mg/2mL
Single intra-articular injection of SM04690
Drug: SM04690
Placebo Comparator: Placebo
Single intra-articular injection of placebo
Drug: Placebo



Primary Outcome Measures :
  1. Change from baseline OA pain in the target knee [ Time Frame: Baseline and Week 13 ]
    Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore at Week 13. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of patients with OA of the knee and hip, including pain, stiffness, and physical functioning of the joints.


Secondary Outcome Measures :
  1. Change from baseline OA pain in the target knee [ Time Frame: Baseline and Week 26 ]
    Change from baseline OA pain in the target knee as assessed by the WOMAC pain subscore at Week 26

  2. Change from baseline OA function in the target knee [ Time Frame: Baseline and Weeks 13 and 26 ]
    Change from baseline OA function in the target knee as assessed by the WOMAC function subscore at Weeks 13 and 26

  3. Change from baseline OA disease activity as assessed by the patient [ Time Frame: Baseline and Weeks 13 and 26 ]
    Change from baseline OA disease activity as assessed by the Patient Global Assessment at Weeks 13 and 26

  4. Change from baseline in joint space width (JSW) of target knee [ Time Frame: Baseline and Week 26 ]
    Change from baseline in JSW as documented by X-ray of the target knee at Week 26



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Established diagnosis of primary femorotibial OA in the target knee for at least 6 months (clinical and radiographic [x-ray] criteria)
  • Radiographic [x-ray] disease Stage 2 or 3 in the target knee according to the Kellgren-Lawrence grading of knee OA
  • Screening pain visual analog scale (VAS) score in the required range for the target knee while on oral symptomatic treatment (if required) at study start
  • Total WOMAC score in the required range for the target knee while on symptomatic oral treatment (if required) at study start
  • Willingness to omit the following for 24 hours prior to all Study Visits, excluding the Screening Visit:

    1. Pain medications
    2. Medications or supplements for the treatment of OA
    3. Participation in a formalized in-office and/or supervised OA disease program (e.g., a prescribed patient education program, physiotherapy, etc.)
  • Full understanding of the requirements of the study and willingness to comply with all study visits and assessments

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Women of childbearing potential (i.e., who are not surgically sterile or postmenopausal as defined by no menstrual periods for 12 consecutive months and no other biological or physiological cause for amenorrhea can be identified); males who are sexually active and have a partner who is capable of becoming pregnant, neither of which have had surgery to become sterilized, who are not using an effective method of birth control (e.g., surgically-implanted hormonal therapy, intrauterine devices or oral birth control with barrier method)
  • Body mass index (BMI) >40
  • Partial or complete joint replacement in the target knee
  • Previous exposure to SM04690
  • Major surgery (e.g., interventional arthroscopy) in the target knee within 12 months prior to any study injection
  • Any planned or elective surgery during the study period
  • Significant and clinically evident misalignment of the target knee, as determined by the Investigator
  • History of malignancy within the last 5 years; however, subjects with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Subjects with other malignancies are eligible if they have been continuously disease free for at least 5 years prior to any study injection
  • Comorbid conditions that could affect pain assessment of the target knee, including, but not limited to, inflammatory rheumatic conditions such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, diabetic neuropathy, pseudogout, gout, and fibromyalgia
  • Participation in a clinical research trial that included the receipt of an investigational product or any experimental therapeutic procedure within 12 weeks prior to any study injection
  • Treatment of the target knee with systemic or intra-articular corticosteroids (e.g., methylprednisolone) within 2 months prior to study start
  • Viscosupplementation (e.g., hyaluronic acid) in the target knee within 6 months prior to study start
  • Effusion of the target knee requiring aspiration within 3 months prior to study start
  • Use of electrotherapy or acupuncture for OA within 4 weeks prior to study start
  • Any known active infections, including suspicion of intra-articular infection, hepatitis B or hepatitis C infection, and/or infections that may compromise the immune system such as human immunodeficiency virus (HIV)
  • Subjects taking prescription medications for OA who have not maintained a stable therapeutic regimen for a minimum of 3 months prior to study start
  • Subjects requiring the chronic use of the following medications:

    1. Opioids, both oral (e.g., tramadol) and transdermal (e.g., fentanyl patches) formulations
    2. Centrally acting analgesics (e.g., duloxetine)
    3. Glucocorticoids (e.g., methylprednisolone) administered by any route, with exception of intranasal and ophthalmic solutions
  • Any chronic condition that has not been well controlled or subjects with a chronic condition who have not maintained a stable therapeutic regimen of a prescription therapy for a minimum of 3 months prior to study start

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02536833


Locations
Layout table for location information
United States, Alabama
Research Site
Mobile, Alabama, United States
United States, Arizona
Research Site
Phoenix, Arizona, United States
Research Site
Tucson, Arizona, United States
United States, California
Research Site
El Cajon, California, United States
Research Site
Rancho Mirage, California, United States
Research Site
Spring Valley, California, United States
United States, Colorado
Research Site
Denver, Colorado, United States
United States, Florida
Research Site
Clearwater, Florida, United States
Research Site
Coral Gables, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Miami, Florida, United States
Research Site
West Palm Beach, Florida, United States
United States, Georgia
Research Site
Woodstock, Georgia, United States
United States, Kansas
Research Site
Newton, Kansas, United States
Research Site
Wichita, Kansas, United States
United States, Kentucky
Research Site
Lexington, Kentucky, United States
United States, Maryland
Research Site
Frederick, Maryland, United States
United States, Massachusetts
Research Site
Boston, Massachusetts, United States
Research Site
Worcester, Massachusetts, United States
United States, Missouri
Research Site
Saint Louis, Missouri, United States
United States, New York
Research Site
Orchard Park, New York, United States
Research Site
Rochester, New York, United States
United States, North Carolina
Research Site
Raleigh, North Carolina, United States
Research Site
Salisbury, North Carolina, United States
United States, Ohio
Research Site
Cincinnati, Ohio, United States
United States, Pennsylvania
Research Site
Duncansville, Pennsylvania, United States
United States, South Carolina
Research Site
Mount Pleasant, South Carolina, United States
United States, South Dakota
Research Site
Rapid City, South Dakota, United States
United States, Tennessee
Research Site
Knoxville, Tennessee, United States
United States, Texas
Research Site
Austin, Texas, United States
Research Site
Houston, Texas, United States
United States, Utah
Research Site
West Layton, Utah, United States
United States, Virginia
Research Site
Charlottesville, Virginia, United States
Research Site
Richmond, Virginia, United States
United States, Wisconsin
Research Site
Franklin, Wisconsin, United States
Sponsors and Collaborators
Samumed LLC
Investigators
Layout table for investigator information
Study Director: Yusuf Yazici, M.D. Samumed LLC
Layout table for additonal information
Responsible Party: Samumed LLC
ClinicalTrials.gov Identifier: NCT02536833    
Other Study ID Numbers: SM04690-OA-02
First Posted: September 1, 2015    Key Record Dates
Last Update Posted: March 13, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Samumed LLC:
OA
Samumed
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Adavivint
Anti-Inflammatory Agents